Sai Parenterals Limited Q1 FY27 earnings call summary

Earnings call of 12 Aug 2026, summarised by AI from the filing.

Sai Parenterals Q1 FY27 consolidated revenue ₹182 cr, EBITDA ₹27 cr at 14.9%, reiterates FY27 guidance of ₹750 cr revenue at around 17% EBITDA.

Key takeaways

1. EBOS renewal Exclusive OTC supply agreement with EBOS renewed 1 July 2026, valued at AUD 202 million (approximately ₹1,300 cr) for 7.5 years.
2. Air freight West Asia disruption delayed consignments; inventory moved by air rather than sea, hitting the quarter's margin.

Original filing on BSE

Sai Parenterals Limited Q1 FY27 results

As filed: Revenue ₹179 cr, EBITDA ₹23.5 cr, PAT ₹7.9 cr, EBITDA margin 13.2%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹179 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹198 cr, EBITDA ₹26.1 cr, PAT ₹13.2 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹198 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +0.2% in 30 days (Nifty 500: −1.5%).
• Q3 FY26: Revenue ₹96.2 cr, EBITDA −₹3.6 cr, PAT −₹6.7 cr, EBITDA margin -3.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹96.2 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (12 Aug 2026), Results deck (12 Aug 2026)
• Q4 FY26: Earnings call (27 May 2026), Results deck (26 May 2026), Results press release (23 May 2026)